Page contentsPage contents Key facts Decision Related medicine information Key facts Invented name ATrynATryn Active substance antithrombin alfa Therapeutic area Haematology-Hemostaseology Decision number P/226/2011 PIP number EMEA-001154-PIP01-11 Pharmaceutical form(s) Powder for solution for infusion Condition(s) / indication(s) Treatment of antithrombin deficiency Route(s) of administration Intravenous use Contact for public enquiries GTC Biotherapeutics UK Limited E-mail: Dick.Scotland@gtc-bio.comTel.: +1 5083705164 Decision type RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) Decision date 27/09/2011 Compliance check done No Decision P/226/2011: EMA decision of 27 September 2011 on the refusal of a product specific waiver for antithrombin alfa (ATryn) (EMEA-001154-PIP01-11)Adopted Reference Number: EMA/710340/2011 English (EN) (77.94 KB - PDF)First published: 18/10/2011 Last updated: 18/10/2011 View Related medicine information ATryn Share this page